

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	Unknown
Filing Date	Unknown
First Named Inventor	Mickie Bhatia
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	10188-18

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-5,780,299	07-14-1998	Ambesi et al.	Entire document and claims
	2	US- 6,174,526	01-16-2001	The Picower Institute	
	3	US- 2002/0012653	01-31-2002	Pang et. al.	
	4	US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	1	WO 01 11011 A2	02-15-2001	Reyes Morayma et al.	Pg. 1, line 26, pg. 8 line 23, pg. 9, line 22, pg. 14, line 22-25, pg. 45, line 16-26, pg. 51, line 6, pg. 52, line 17	
	2	WO 02 064748 A2	08-22-2002	Furcht, Leo et al.	Pg. 9, line 29, pg. 13, line 5, pg. 21, line 23, pg. 22, line 2, pg. 32, line 6-9, pg. 39, line 25-28, Claims 3, 20, 27, 29, 35, 52, 54, 57, 59, 61, 68, 73	
	3	WO 02 083187 A	10-24-2002	Islet Technology Inc.	Pg. 21, line 6, pg. 23, line 21, pg. 35, line 21, pg. 37, line 9	
	4	EP 1 254 952 A	11-06-2002	Kyowa et. al.		
	5	WO 02/13760 A2	02-21-2002	New York Medical et.al.		
	6	WO 02/09650 A2	02-7-2002	New York Medical		
	7	WO 01/21767 A2	03-29-2001	Morphogen Pharma.		
	8	WO 01/21766 A2	03-29-2001	Cell Science		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	Unknown
Filing Date	Unknown
First Named Inventor	Mickie Bhatia
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	10188-18

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	HESS, David et al., Bone marrow-derived stem cells initiate pancreatic regeneration, Nature Biotechnology, 21(7), pgs. 763-770, 2003, XP002265780.	
	2	ORTIZ, Mariaestela et. al., Functional characterization of a novel hematopoietic stem cell and its place in the c-kit maturation pathway in bone marrow cell development, Immunity, 10(2), pgs. 173-182, 1999, XP001156831.	
	3	SPRINGER, Matthew L. et al., Not the usual suspects: the unexpected sources of tissue regeneration, Journal of Clinical Investigation, 107(11), pgs. 1355-1356, 2001, XP002265781.	
	4	TSAI, Robert Y. L. et al., Plasticity, niches, and the use of stem cells, Developmental Cell, 2(6), pgs. 707-712, 2002, XP009023173.	
	5	BEILHACK, George F. et al., Purified allogenic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice, DATABASE CA 'Online', Chemical Abstracts Service, Columbus, OH, Database accession no. 139:875 CA, XP002265783. Abstract & Diabetes (2003), 52(1), pgs. 59-68, 2003.	
	6	ENDE, Norman et al., NOD/LtJ type I diabetes in mice and the effect of stem cells (Berashis) derived from human umbilical cord blood, DATABASE BIOSIS 'Online', Biosciences Information Service, Philadelphia, PA, Database accession no. PREV200300399271, XP002265784. Abstract & Journal of Medicine, vol. 33, no. 1-4, 2002, pgs. 181-187, ISSN: 0025-7850.	
	7	IKEHARA, S. et. al., Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation, Proc. Natl. Acad. Sci, USA 82, 7743-7747, 1985.	
	8	Than, S. et. al., Journal of Exp. Med., 176(40), 1233-1238, 1992.	
	9		
	10		
	11		

Examiner  
Signature

/Ruth A. Davis/

Date  
Considered

02/28/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RAD/